Sonidegib

Definition

An orally bioavailable small-molecule smoothened (Smo) antagonist with potential antineoplastic activity. Sonidegib selectively binds to the hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.

Also known as (1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2- methyl-4'-(trifluoromethoxy)-, rel-, Erismodegib, LDE 225, LDE-225, LDE225, Odomzo, Smoothened Antagonist LDE225, SONIDEGIB — per NCIT

Also identified as

• ATC L01XJ02 per RXNORM
• NCIT NCIT:C82385 per NCIT
• SCTID 715187001 per RXNORM
• SCTID 781303007 per RXNORM
• UNII 0RLU3VTK5M per RXNORM

Indications